ABBV

NYSE

AbbVie Inc.

Latest disclosureOctober 2, 2026

Insider score Why 0?: 0/ 100
Qualifying buys · 30d: $0

0 purchases · 1 sales

Price by TradingView

Insider transactions 21

Limited filing history

Filters

Last 30 daysNo qualifying insider buying. No qualifying insider sales.

Sale disclosed

Nicholas Donoghoe

EVP, CHIEF BUS/STRAT OFFICER

Common Stock, $0.01 par value

Reported value: $8.18M
Reported price: $250.00 / share

Reporting insider	Security / transaction	Amount / price	Value	Traded / disclosed	Source
EVP, CHIEF BUS/STRAT OFFICER	Common Stock, $0.01 par valueSale	32,710$250.00 / share	$8.18M	Aug 14Filed Aug 18 · 4d later	SEC filing

Congress transactions 12

All Congress filings

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for the member.

Pete SessionsReporting House member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: September 14, 2026

Purchase disclosed

AbbVie Inc. Common Stock · Stock

The filing reports a purchase for the member.

AAAlan ArmstrongReporting Senate member

Reported amount: $15,001 – $50,000Reported range; exact amount not disclosed.
Trade date: March 27, 2026

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for a joint account.

Josh GottheimerReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: May 5, 2026

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 18, 2025

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: December 8, 2025

Purchase disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a purchase for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: April 28, 2025

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: January 24, 2025

Purchase disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a purchase for the member.

Julia LetlowReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 23, 2024

Partial sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a partial sale for a joint account.

Julie JohnsonReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: November 13, 2025

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 31, 2025

Purchase disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a purchase for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 30, 2025

Sale disclosed

AbbVie Inc. Common Stock (ABBV) · Stock

The filing reports a sale for a spouse.

Lisa McClainReporting House member

Reported amount: $1,001 – $15,000Reported range; exact amount not disclosed.
Trade date: October 30, 2025

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001551152
Latest public acceptance: Oct 2, 2026, 09:00 PM UTC
Score calculated: Oct 7, 2026, 12:08 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.

Insider activity can have many explanations. Signal Strength is not a probability of profit or a recommendation to trade.

Reporting insider

Security / transaction

Amount / price

Value

Traded / disclosed

Source

EVP, CHIEF BUS/STRAT OFFICER

Common Stock, $0.01 par valueSale

32,710$250.00 / share

$8.18M

Aug 14Filed Aug 18 · 4d later

SEC filing

Why this buying score?

No qualifying common-equity purchases

No eligible common-equity purchase is public by this cutoff within 180 transaction-date days. Other instruments, exercises and routine activity do not contribute purchase points.

+0 pts

This score describes qualifying insider purchases at issuer level. Read the methodology

Sources and coverage

Limited filing history · Market-wide discovery does not establish complete company history. View coverage

Source: SEC EDGAR · Form 4
Issuer CIK: 0001551152
Latest public acceptance: Oct 2, 2026, 09:00 PM UTC
Score calculated: Oct 7, 2026, 12:08 AM UTC
Parser: form4-parser-1.5
Classifier: form4-classifier-1.1
Scoring methodology: insider-experimental-1.1
Availability: Public filing time, not trade date

Open a transaction's SEC filing for the primary evidence. A code P may describe an open-market or private purchase; classification is not proof of intent.